Evidence map›Paper›PMID 34867130›Full record

ArticleInternational journal of peptide research and therapeutics2022

ACE2 Peptide Fragment Interaction with Different S1 Protein Sites.

Aleksei Kuznetsov, Piret Arukuusk, Heleri Härk, Erkki Juronen, Mart Ustav, Ülo Langel, Jaak Järv

Open access · bronzeAbstract read
In one paragraph

Article in International journal of peptide research and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Aleksei KuznetsovInstitute of Chemistry, University of Tartu, Tartu, Estonia.
Piret ArukuuskInstitute of Technology, University of Tartu, Tartu, Estonia.
Heleri HärkInstitute of Technology, University of Tartu, Tartu, Estonia.
Erkki JuronenIcosagen Cell Factory OÜ, Tartu, Estonia.
Mart UstavInstitute of Technology, University of Tartu, Tartu, Estonia.
Ülo LangelInstitute of Technology, University of Tartu, Tartu, Estonia.
Jaak JärvInstitute of Chemistry, University of Tartu, Tartu, Estonia.ORCID 0000-0003-1042-2701
University of Tartu · EEIcosagen (Estonia) · EEStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We study the effect of the peptide QAKTFLDKFNHEAEDLFYQ on the kinetics of the SARS-CoV-2 spike protein S1 binding to angiotensin-converting enzyme 2 (ACE2), with the aim to characterize the interaction mechanism of the SARS-CoV2 virus with its host cell. This peptide corresponds to the sequence 24-42 of the ACE2 α1 domain, which marks the binding site for the S1 protein. The kinetics of S1-ACE2 complex formation was measured in the presence of various concentrations of the peptide using bio-layer interferometry. Formation of the S1-ACE2 complex was inhibited by the peptide in cases where it was preincubated with S1 protein before the binding experiment. The kinetic analysis of S1-ACE2 complex dissociation revealed that preincubation stabilized this complex, and this effect was dependent on the peptide concentration as well as the preincubation time. The results point to the formation of the ternary complex of S1 with ACE2 and the peptide. This is possible in the presence of another binding site for the S1 protein beside the receptor-binding domain for ACE2, which binds the peptide QAKTFLDKFNHEAEDLFYQ. Therefore, we conducted computational mapping of the S1 protein surface, revealing two additional binding sites located at some distance from the main receptor-binding domain on S1. We suggest the possibility to predict and test the short protein derived peptides for development of novel strategies in inhibiting virus infections. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10324-7.

Indexed as

ACE2 peptide fragmentAllosteric binding siteBio-layer interferometryPeptidePeptide binding kineticsPeptide dockingSARS-CoV-2 spike protein

Identifiers

PMID34867130
PMCPMC8634746
OpenAlexW3216396453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.